Sectors - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/pharma/ The leading site for news and procurement in the pharmaceutical industry Tue, 06 Jun 2023 23:00:00 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.2 https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2022/01/cropped-Pharmaceutical-Technology-Favicon-150x150.png Sectors - Pharmaceutical Technology https://www.pharmaceutical-technology.com/sector/pharma/ 32 32 Risk adjusted net present value: What is the current valuation of Orchard Therapeutics’s OTL-201? https://www.pharmaceutical-technology.com/data-insights/otl-201-orchard-therapeutics-net-present-value/ https://www.pharmaceutical-technology.com/data-insights/otl-201-orchard-therapeutics-net-present-value/#respond Tue, 06 Jun 2023 17:50:46 +0000 https://www.pharmaceutical-technology.com/data-insights/otl-201-orchard-therapeutics-net-present-value/feed/ 0 Risk adjusted net present value: What is the current valuation of PolyPid’s Doxycycline hyclate CR? https://www.pharmaceutical-technology.com/data-insights/doxycycline-hyclate-cr-polypid-net-present-value/ https://www.pharmaceutical-technology.com/data-insights/doxycycline-hyclate-cr-polypid-net-present-value/#respond Tue, 06 Jun 2023 17:50:03 +0000 https://www.pharmaceutical-technology.com/data-insights/doxycycline-hyclate-cr-polypid-net-present-value/feed/ 0 Risk adjusted net present value: What is the current valuation of Lineage Cell Therapeutics’s OPC-1? https://www.pharmaceutical-technology.com/data-insights/opc-1-lineage-cell-therapeutics-net-present-value/ https://www.pharmaceutical-technology.com/data-insights/opc-1-lineage-cell-therapeutics-net-present-value/#respond Tue, 06 Jun 2023 17:50:03 +0000 https://www.pharmaceutical-technology.com/data-insights/opc-1-lineage-cell-therapeutics-net-present-value/feed/ 0 Risk adjusted net present value: What is the current valuation of RegenxBio’s RGX-111? https://www.pharmaceutical-technology.com/data-insights/rgx-111-regenxbio-net-present-value/ https://www.pharmaceutical-technology.com/data-insights/rgx-111-regenxbio-net-present-value/#respond Tue, 06 Jun 2023 17:50:03 +0000 https://www.pharmaceutical-technology.com/data-insights/rgx-111-regenxbio-net-present-value/feed/ 0 Deudomperidone by CinRx Pharma for Diabetic Gastroparesis: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/deudomperidone-cinrx-pharma-diabetic-gastroparesis-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/deudomperidone-cinrx-pharma-diabetic-gastroparesis-likelihood-of-approval/#respond Mon, 05 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/deudomperidone-cinrx-pharma-diabetic-gastroparesis-likelihood-of-approval/feed/ 0 LB-001 by Logicbio Therapeutics for Methylmalonic Acidemia: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/lb-001-logicbio-therapeutics-methylmalonic-acidemia-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/lb-001-logicbio-therapeutics-methylmalonic-acidemia-likelihood-of-approval/#respond Mon, 05 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/lb-001-logicbio-therapeutics-methylmalonic-acidemia-likelihood-of-approval/feed/ 0 AS-1763 by Carna Biosciences for Follicular Lymphoma: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/as-1763-carna-biosciences-follicular-lymphoma-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/as-1763-carna-biosciences-follicular-lymphoma-likelihood-of-approval/#respond Mon, 05 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/as-1763-carna-biosciences-follicular-lymphoma-likelihood-of-approval/feed/ 0 Poly-ICLC by Oncovir for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/feed/ 0 (Chlorthalidone + losartan) by Laboratorios Silanes for Idiopathic (Essential) Hypertension: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/chlorthalidone-losartan-laboratorios-silanes-idiopathic-essential-hypertension-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/chlorthalidone-losartan-laboratorios-silanes-idiopathic-essential-hypertension-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/chlorthalidone-losartan-laboratorios-silanes-idiopathic-essential-hypertension-likelihood-of-approval/feed/ 0 Pexastimogene devacirepvec by Sillajen Biotherapeutics for Gastric Cancer: Likelihood of Approval https://www.pharmaceutical-technology.com/data-insights/pexastimogene-devacirepvec-sillajen-biotherapeutics-gastric-cancer-likelihood-of-approval/ https://www.pharmaceutical-technology.com/data-insights/pexastimogene-devacirepvec-sillajen-biotherapeutics-gastric-cancer-likelihood-of-approval/#respond Tue, 06 Jun 2023 23:00:00 +0000 https://www.pharmaceutical-technology.com/data-insights/pexastimogene-devacirepvec-sillajen-biotherapeutics-gastric-cancer-likelihood-of-approval/feed/ 0